These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36707779)

  • 1. Baseline characteristics and treatment response predictive of nAMD outcomes with ranibizumab therapy in treatment-naive patients: the RACER subgroup analysis.
    Tsai CY; Wu CL; Cheng CK; Shen YD; Wu WC; Wu PC; Tsai A; Chen JT
    BMC Ophthalmol; 2023 Jan; 23(1):39. PubMed ID: 36707779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 12-month, prospective, observational study of ranibizumab in treatment-naïve Taiwanese patients with neovascular age-related macular degeneration: the RACER study.
    Wu WC; Chen JT; Tsai CY; Wu CL; Cheng CK; Shen YD; Tsai A; Wu PC
    BMC Ophthalmol; 2020 Nov; 20(1):462. PubMed ID: 33238968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration.
    Stoller GL; Kokame GT; Dreyer RF; Shapiro H; Tuomi LL
    JAMA Ophthalmol; 2016 May; 134(5):545-553. PubMed ID: 27010625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration.
    Razavi S; Kodjikian L; Giocanti-Aurégan A; Dufour I; Souied E
    BMC Ophthalmol; 2021 Feb; 21(1):90. PubMed ID: 33596867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing of Peak Vision Gains in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab.
    Khurana RN; Chang L; Day BM; Ghanekar A; Stoilov I
    Ophthalmol Retina; 2020 Aug; 4(8):760-766. PubMed ID: 32387055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL Study.
    Larsen M; Waldstein SM; Priglinger S; Hykin P; Barnes E; Gekkieva M; Das Gupta A; Wenzel A; Monés J;
    Ophthalmol Retina; 2018 Feb; 2(2):134-142. PubMed ID: 31047340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-year results of a combined regimen of aflibercept treatment in three types of choroidal neovascular membrane in the wet form of age-related macular degeneration: Real-life evidence in the Czech Republic.
    Stepanov A; Nemcansky J; Veith M; Manethova K; Stredova M; Pencak M; Tarkova A; Studnicka J
    Eur J Ophthalmol; 2021 Sep; 31(5):2488-2495. PubMed ID: 33198503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: One-Year Results of the Randomized Canadian Treat-and-Extend Analysis Trial with Ranibizumab Study.
    Kertes PJ; Galic IJ; Greve M; Williams RG; Rampakakis E; Scarino A; Sheidow T
    Ophthalmology; 2019 Jun; 126(6):841-848. PubMed ID: 30677465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
    Li E; Donati S; Lindsley KB; Krzystolik MG; Virgili G
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012208. PubMed ID: 32374423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualized Ranibizumab Regimen Driven by Stabilization Criteria for Central Retinal Vein Occlusion: Twelve-Month Results of the CRYSTAL Study.
    Larsen M; Waldstein SM; Boscia F; Gerding H; Monés J; Tadayoni R; Priglinger S; Wenzel A; Barnes E; Pilz S; Stubbings W; Pearce I;
    Ophthalmology; 2016 May; 123(5):1101-11. PubMed ID: 26896124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visual benefit versus visual gain: what is the effect of baseline covariants in the treatment arm relative to the control arm? A pooled analysis of ANCHOR and MARINA.
    Tufail A; Margaron P; Guerin T; Larsen M
    Br J Ophthalmol; 2020 May; 104(5):672-677. PubMed ID: 31562118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year outcome of ranibizumab for neovascular age-related macular degeneration: a thorough analysis in a real-world clinical setting.
    Gabai A; Veritti D; Lanzetta P
    Eur J Ophthalmol; 2014; 24(3):396-401. PubMed ID: 24242222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of BRIGHTER.
    Tadayoni R; Waldstein SM; Boscia F; Gerding H; Pearce I; Priglinger S; Wenzel A; Barnes E; Gekkieva M; Pilz S; Monés J;
    Ophthalmology; 2016 Jun; 123(6):1332-44. PubMed ID: 27039022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
    Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Ng P; Pecheur FL; McAllister IL
    JAMA Ophthalmol; 2019 Apr; 137(4):372-379. PubMed ID: 30676617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM; Chen E; Mariani A; Major JC;
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
    Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
    Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Value of Retinal Morphology for Visual Acuity Outcomes of Different Ranibizumab Treatment Regimens for Neovascular AMD.
    Waldstein SM; Wright J; Warburton J; Margaron P; Simader C; Schmidt-Erfurth U
    Ophthalmology; 2016 Jan; 123(1):60-9. PubMed ID: 26481821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simulating an Anti-Vascular Endothelial Growth Factor Switch in Neovascular Age-Related Macular Degeneration: A HARBOR Subanalysis.
    Zarbin M; Tsuboi M; Hill LF; Stoilov I
    Ophthalmology; 2019 Jun; 126(6):849-855. PubMed ID: 30641096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial.
    Sahni J; Dugel PU; Patel SS; Chittum ME; Berger B; Del Valle Rubido M; Sadikhov S; Szczesny P; Schwab D; Nogoceke E; Weikert R; Fauser S
    JAMA Ophthalmol; 2020 Sep; 138(9):955-963. PubMed ID: 32729888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results.
    Wykoff CC; Croft DE; Brown DM; Wang R; Payne JF; Clark L; Abdelfattah NS; Sadda SR;
    Ophthalmology; 2015 Dec; 122(12):2514-22. PubMed ID: 26391465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.